Core Viewpoint - The company, 科笛-B (02487), experienced a significant stock price increase of over 14% despite reporting a substantial decline in revenue and an increase in net loss for the first half of the year [1] Financial Performance - Revenue for the first half of the year decreased by 30.6% to approximately 66.3 million HKD [1] - The net loss amounted to approximately 239 million HKD, reflecting a year-on-year increase of about 19.1% [1] Strategic Decisions - The revenue decline was primarily attributed to the company's cautious decision to terminate its agency partnership with the American skincare brand, 欧玛, due to macroeconomic policies and international environmental impacts [1] - Resources are being reallocated towards the commercialization of new products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which are expected to have greater market potential and higher return on investment [1] Fundraising and Allocation - The company plans to issue a total of 28.9 million placement shares at a price of 8.40 HKD per share, representing a discount of approximately 12.04% from the previous closing price of 9.55 HKD [1] - The net proceeds from the placement are expected to be around 240 million HKD, with 45% allocated for preclinical research and development, clinical trials, and production facility layout in areas such as localized fat management, hair diseases, and skin diseases [1] - Another 45% will be used for marketing, channel expansion, and brand building for CU-40102 and CU-10201, while the remaining 10% will be allocated for working capital and general corporate purposes [1]

Group 1 - The core viewpoint of the news is that 科笛-B (02487) experienced a significant stock price increase of over 14% despite reporting a substantial decline in revenue and an increase in net loss for the first half of the year [1] - The company's revenue decreased by 30.6% year-on-year to approximately 66.3 million HKD, while the net loss increased by about 19.1% to approximately 239 million HKD [1] - The decline in revenue is attributed to the company's decision to terminate its agency cooperation with the US skincare brand 欧玛 due to macroeconomic policies and international environment impacts, reallocating resources to new products with higher market potential [1] Group 2 - 科笛 plans to issue a total of 28.9 million placement shares at a price of 8.40 HKD per share, representing a discount of approximately 12.04% to the previous trading day's closing price of 9.55 HKD [2] - The net proceeds from the placement are expected to be approximately 240 million HKD, with 45% allocated for preclinical research and development, clinical trials, and production facility layout in areas such as localized fat management and skin diseases [2] - Another 45% of the proceeds will be used for marketing, channel expansion, and brand building for the new products CU-40102 and CU-10201, while the remaining 10% will be used for working capital and general corporate purposes [2]

Group 1 - The core point of the article is that Codex Group (stock code: 2487) announced a share placement to raise approximately HKD 240 million through the issuance of 28,904,000 new shares at a price of HKD 8.40 per share, which represents a discount of about 12.0% from the previous closing price of HKD 9.55 [1] - The placement shares represent approximately 9.1% of the existing issued share capital and about 8.3% of the enlarged share capital after completion [1] - The placement is managed by BOC International and Haitong International as placement agents, and the completion is expected by September 5, 2025 [1] Group 2 - Codex Group is an investment holding company focused on developing innovative and comprehensive solutions to meet the diverse and evolving needs of patients and consumers in the dermatology treatment and care market [2] - Approximately HKD 110 million of the raised funds will be allocated for preclinical research and clinical trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [2] - Another HKD 110 million will be used for marketing activities, channel expansion, and brand building for CU - 40102 (topical finasteride spray) and CU - 10201 (topical 4% minocycline foam) [2] - The remaining HKD 20 million will be allocated for working capital and other general corporate purposes [2]

Core Viewpoint - The company, 科笛-B (02487), has announced a share placement agreement to issue approximately 28.9 million shares at a price of HKD 8.40 per share, representing about 9.05% of its existing shares, with the net proceeds expected to be around HKD 240 million [1] Group 1: Share Placement Details - The placement price of HKD 8.40 per share reflects a discount of approximately 12.04% compared to the closing price of HKD 9.55 on the announcement date [1] - The share placement is facilitated by placement agents who will act on behalf of the company [1] Group 2: Use of Proceeds - Approximately 45% of the net proceeds will be allocated for clinical research and trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% of the net proceeds will be used for marketing activities, channel expansion, and brand building for CU-40102 (a topical finasteride spray) and CU-10201 (a topical 4% minocycline foam) [1] - The remaining 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - The company, 科笛-B (02487), has entered into a placement agreement to issue 28.904 million shares at a price of HKD 8.40 per share, representing approximately 9.05% of the company's issued shares as of the announcement date, with a discount of about 12.04% compared to the closing price of HKD 9.55 on August 28, 2025 [1] Summary by Categories Placement Details - The placement agreement was signed with placement agents on August 28, 2025, to facilitate the subscription of shares at HKD 8.40 each [1] - The total number of shares to be placed is 28.904 million, which is about 9.05% of the company's issued shares excluding treasury shares [1] - The placement price represents a discount of approximately 12.04% from the closing price on the same day [1] Expected Net Proceeds - The estimated net proceeds from the placement are approximately HKD 240 million after deducting related expenses and costs [1] Use of Proceeds - About 45% of the net proceeds will be allocated for clinical research and trials related to localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - Approximately 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

本公告並不構成在美國或在有關要約屬違法的任何其他司法權區購買或認購任何證券之提呈要 約或招攬，亦不構成其任何一部分。本公告提及的證券並無且將不會根據不時修訂之《1933年 美國證券法》（《美國證券法》）或美國任何其他州之證券法律登記，且不得在美國提呈發售或出 售，惟根據《美國證券法》的規定進行登記，或適用豁免登記，或進行毋須遵守有關登記規定的 交易則除外。本公司無意按照《美國證券法》於美國登記本公告所述任何證券，亦無意於美國公 開發售證券。 Cutia Therapeutics 科笛集團 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何文本概不得直接或間接在美國，或在發放或派發本公告屬違法的任何其他司法 權區內發放或派發。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 （於開曼群島註冊成立的有限公司） （股份代號：2487） 根據一般授權配售新股 整體協調人兼配售代理 根據一般授權配售新股 2025年8月28日（交易時 ...

Group 1 - Mr. Tao Derun has resigned as an independent non-executive director and as a member of the board audit committee and nomination committee, effective from August 28, 2025 [1] - Mr. Zhang Zhishong has been appointed as an independent non-executive director, effective from August 28, 2025 [1] - Following Mr. Tao's resignation, Mr. Zhang has also been appointed as a member of the audit committee and nomination committee, effective from August 28, 2025 [1] - Dr. Xie Qin and Mr. Ye Xiaoxiang have been appointed as members of the board nomination committee, effective from August 28, 2025 [1]

Core Viewpoint - The company announced the resignation of Chen Shiting from her positions as company secretary, authorized representative, and legal process agent, effective August 28, 2025. Liang Zhijie has been appointed to fill the vacancy starting from the same date [1]. Group 1 - Chen Shiting has resigned from her roles within the company [1] - Liang Zhijie has been appointed as the new company secretary and authorized representative [1] - The changes in personnel are effective from August 28, 2025 [1]

Core Viewpoint - The company announced the resignation of Ms. Chen Shiting from her positions as company secretary, authorized representative, and legal representative, effective from August 28, 2025 [1] Group 1 - Ms. Chen Shiting has submitted her resignation [1] - Mr. Liang Zhijie has been appointed as the new company secretary, authorized representative, and legal representative to fill the vacancy left by Ms. Chen [1] - The effective date for both the resignation and the appointment is August 28, 2025 [1]

智通财经APP讯，科笛-B(02487)发布公告，陈诗婷女士已提出辞呈，辞任(1)公司公司秘书;(2)授权代表; 及(3)法律程序代理人职务，自2025年8月28日起生效。 梁志杰先生已获委任为公司秘书、授权代表及法律程序代理人以填补陈女士的空缺，自2025年8月28日 起生效。 ...